The acquisition of a European-based medical CDMO expands manufacturing in Europe and India, strengthens the medical vertical, and is expected to be accretive to earnings in fiscal 2027. The deal enhances global reach, unlocks synergies, and positions the combined business for accelerated growth.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.